This medication is applied across domains where additional symptomatic support is needed to address acute ocular pain that often follows intraocular procedures, such as cataract surgery. It is used for managing the symptoms related to physical discomfort, which contributes to easing the overall symptom load and helps patients cope more steadily during the initial recovery phase.

It is considered relevant for easing symptoms related to inflammatory or irritative states by addressing the symptomatic manifestations of acute postoperative inflammation in the eye. This is commonly used to help with the cluster of symptoms, including eye redness and swelling, providing supportive relief that assists with maintaining functional stability when symptoms are more noticeable. This therapeutic use is generally applied as supportive care for adult patients who have undergone lens replacement, and is relevant for easing the symptomatic manifestations of postoperative ocular pain and inflammation.

“The medication is used to provide symptomatic relief that assists with maintaining functional stability.”

Key Therapeutic Focus: Acute Post-Surgical Discomfort

This is commonly used to help with the cluster of symptoms related to physical discomfort and inflammatory states, which assists with maintaining functional stability and supports general well-being during the symptomatic periods.

Regulatory References

1. NIH DailyMed official labeling

Eligibility Map: Who can and cannot use Броксинак — Official Regulatory Information

Eligibility Scope

| Populations for whom use is allowed (as stated in label): | Adult patients (18+); Older adult patients (no differences in safety/effectiveness noted). | Populations for whom use is not recommended (if applicable): | Pregnant women prior to the third trimester (use conditional on risk/benefit); Nursing mothers (caution advised). | Populations for whom use is contraindicated: | Patients with known hypersensitivity to bromfenac or other NSAIDs that precipitate asthma or urticaria. Use is prohibited during the third trimester of pregnancy. | Age-related eligibility rules: | Pediatric population (under 18): Safety and effectiveness have not been established. | Condition-specific eligibility rules: | Use is not studied in patients with hepatic or renal impairment. Caution is mandatory for patients with bleeding tendencies or corneal risk factors (e.g., diabetes mellitus). | Pregnancy and lactation eligibility status (if explicitly documented): | Pregnancy (Third Trimester) is contraindicated. Lactation is conditional on risk assessment. | Eligibility-related restrictions: | Must not be administered while wearing contact lenses.

Eligibility Classifications (High-Level)

| Eligibility severity classification (as defined in official documents): | Contraindicated, Use Not Established, Caution, Not Studied. | Regulatory basis (EMA / FDA / etc.): | The official regulatory profile is based on prescribing information from authorities such as the FDA and EMA. | Eligibility-context constraints (as defined in official documents): | Constraints include NSAID cross-sensitivity, physiological state prohibition (late pregnancy), and excipient-based restriction (contact lenses).

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is contraindicated in patients with known hypersensitivity to bromfenac or other NSAIDs that precipitate asthma or urticaria.
• Safety and effectiveness have not been established for the pediatric population.
• Use is prohibited during the third trimester of pregnancy.
• Caution is required for use in patients with bleeding tendencies or corneal risk factors such as diabetes mellitus.

Connection to the overall eligibility profile (2–4 sentences): Regulatory documents define eligibility primarily by establishing mandatory contraindications based on allergic status and late pregnancy status. Use is limited to the adult population, as safety and efficacy have not been established for those under 18. Furthermore, official labeling advises caution for specific patient groups, including nursing mothers and individuals with certain pre-existing corneal conditions.

The official regulatory profile for Bromfenac ophthalmic solution focuses on local pharmacodynamic risks and administration-timing requirements, reflecting the minimal systemic absorption of the topical form. No metabolic (CYP enzyme) or transporter-mediated interactions are explicitly documented, and no systemic drug-drug combinations are formally listed as contraindicated in official prescribing information. The documented interactions involve additive risk and procedural constraints related to the eye's healing environment.

Administration-Timing and Specific Cautions

The mechanism of action for Броксинак (Bromfenac) is defined by its specific influence on the pathways that regulate inflammation. The compound primarily acts by modulating enzyme activity to inhibit the production of chemical mediators.

Inhibition of the Cyclooxygenase-2 (COX-2) Enzyme

Броксинак acts as an inhibitor of the Cyclooxygenase-2 (COX-2) enzyme, which facilitates the conversion of precursor molecules into inflammatory prostaglandins. This action modifies the early molecular steps that affect systemic physiological outcomes, directly engaging mechanisms that modulate activity within pathways associated with heightened processes.

Reduction of Pro-inflammatory Mediator Synthesis

By blocking the COX-2 enzyme, Броксинак inhibits the synthesis of prostaglandins, resulting in reduced mediator activity. This affects the signaling patterns and results in the reduction of signaling associated with heightened physiological responses in the affected pathway.

Influence on Peripheral Signaling Dynamics

The reduction in inflammatory mediators affects the activity level of peripheral nociceptors. This engages mechanisms that influence feedback regulation within pathways and influences physiological adjustments that impact pathway activity.

Броксинак is used as a topical ophthalmic solution, strictly administered to the surface of the affected eye. The standard regimen involves instilling one drop per application. The frequency of use is standardized but varies based on the specific concentration. Some formulations (e.g., 0.07% strength) utilize a once daily (QD) schedule, while other strengths (e.g., 0.075% and 0.09%) may be prescribed for use twice daily (BID).

The medicine is used as a short-term course with a clearly defined duration. Administration typically begins either one day prior to, or the day immediately following, ocular surgery. The overall treatment is generally maintained through the first 14 days of the post-operative phase, and administration is generally not continued beyond this two-week limit.

Specific procedural requirements govern its proper administration. If other topical eye medications are concurrently used, a minimum interval of 5 minutes must separate the application of each different drop to ensure optimal delivery. Furthermore, the drops must not be administered while wearing contact lenses, and lenses should only be reinserted after a short waiting period. Use in patients under 18 years of age is not established, as clinical data for this population is unavailable.

Research Evidence / Overview of Studies

Evaluating Efficacy in Crohn's Disease (CD)

The majority of clinical investigations focused on the use of this drug in individuals diagnosed with moderately active Crohn's disease. The studies examined the relationship between the drug and clinical outcomes in patients with moderately active Crohn's disease (CD).

Key research assessed changes in inflammatory markers over time. These trials focused on outcomes such as C-Reactive Protein (CRP) levels and mucosal healing rates.

Associated Findings

The mechanism of the drug has been explored in preclinical studies.

Research examined the profile of adverse events in patients with mild-to-moderate CD. Clinical trials focused on patients with mild-to-moderate disease.

Early trials showed that the drug was associated with changes in reported pain and fatigue associated with Crohn’s disease.

Combination Therapy Studies

Researchers explored whether using the drug in combination with conventional immunomodulators was associated with more favorable outcomes. Studies explored whether the combination was associated with changes in remission rates compared to monotherapy.

Common questions about Броксинак (FAQ)

Q: Can I use this medicine if I wear contact lenses?

A: Regulatory documents state that soft contact lenses should be removed prior to drop administration. This is because the preservative in the solution can be absorbed by soft lenses. Official product information advises waiting a period of 10 to 15 minutes before reinserting contact lenses.

Q: Does this drug interact with or affect how other oral medicines work?

A: Regulatory documents indicate that due to the low systemic absorption of the topical eye drops, documented drug-drug interactions with oral medications are minimal or absent. However, official labeling identifies a potential for increased bleeding risk when used concurrently with other medications that affect clotting.

Q: How long can I safely continue to use the drops after my eye surgery?

A: The treatment course is defined for a short duration following eye surgery. Administration is typically maintained through the first 14 days following the procedure. Regulatory documents advise against continued use beyond this two-week period, which is the duration advised in official documents.

Q: What is the mechanism of action for the anti-inflammatory effect?

A: Броксинак is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and works by blocking a specific enzyme called cyclooxygenase-2 (COX-2). By inhibiting this enzyme, the medication stops the synthesis of prostaglandins, which are chemical mediators responsible for triggering inflammation and pain.

Q: What do I do if I accidentally miss a dose?

A: If a dose is missed, patient instructions suggest administering it as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose is usually skipped to continue the regular schedule. Dosing instructions state that a double dose should not be used to make up for a missed dose.

Q: Is this medicine available as a generic version or only under the brand name Броксинак?

A: The active ingredient in Броксинак is bromfenac ophthalmic solution. This compound is available under various brand names and as generic formulations that have been approved by regulatory bodies worldwide.

Q: Can I use these drops in both eyes if only one eye had surgery?

A: Dosing instructions refer to application in the 'affected eye' or 'affected eye(s).' While official guidelines emphasize the need for caution to prevent cross-contamination, patient instructions for some formulations advise using a single bottle for only one eye.

Q: What should I do if the bottle tip touches my finger or eye?

A: Regulatory information states that the dropper tip should not be allowed to touch any surface, including your fingers, eye, or eyelids. Contamination risks are cited as a reason to prevent the spread of bacteria, which can potentially cause eye infections and serious damage to the eye.

The official regulatory labeling for bromfenac ophthalmic solution (Броксинак) establishes specific requirements for storage and disposal to maintain sterility and stability. The medication must be kept in its original, tightly closed container and stored at Controlled Room Temperature, defined as 15 C to 25 C (59 F to 77 F). The product must be protected from freezing, excessive heat, moisture, and direct light. To prevent contamination, patients must avoid touching the dropper tip to any surface. For safety, the solution must be stored out of the sight and reach of children. Unused or expired solution should not be flushed down the sink or toilet but must be disposed of according to local regulations, often by utilizing community drug take-back programs.